This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
REGNNegative Net Change PBYINegative Net Change RAREPositive Net Change MREONo Net Change
biotechnology biotechs earnings medical pharmaceuticals
Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines
by Zacks Equity Research
Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.
RHHBYPositive Net Change PBYINegative Net Change ADMAPositive Net Change
biotechs
Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues outpace estimates in the fourth quarter of 2023. Strong growth in proprietary products drives year-over-year revenues.
ALKSPositive Net Change PBYINegative Net Change STOKNegative Net Change
biotechs
Small AI Companies Soar After Chip Giant Reveals Stake
by Bryan Hayes
Through its SEC disclosure, Nvidia provided investors with more evidence of its long-term growth plan.
NVDANegative Net Change ARMPositive Net Change NNOXNegative Net Change SOUNNegative Net Change
artificial-intelligence autonomous-vehicles biotechs earnings investing magnificent-7 medical-devices self-driving-cars tech-stocks
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
IONSPositive Net Change NTLAPositive Net Change RCUSPositive Net Change CCCCPositive Net Change
biotechnology biotechs
Why Axsome (AXSM) Might Surprise This Earnings Season
by Zacks Equity Research
Axsome (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AXSMPositive Net Change
biotechs medical
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
by Zacks Equity Research
Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.
BIIBNegative Net Change GILDNegative Net Change VRTXPositive Net Change CBAYPositive Net Change CRSPNegative Net Change
biotechnology biotechs
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.
BMRNPositive Net Change MRNAPositive Net Change EXASPositive Net Change NTLAPositive Net Change
biotechnology biotechs earnings medical
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
BMRNPositive Net Change MRNAPositive Net Change BEAMPositive Net Change AMRNNegative Net Change NTLAPositive Net Change
biotechs
Where Are Biotech ETFs Headed After Q4 Earnings?
by Yashwardhan Jain
Look into how Biotech ETFs performed after Q4 earnings.
BIIBNegative Net Change AMGNNegative Net Change GILDNegative Net Change IBBPositive Net Change XBIPositive Net Change BBHNegative Net Change PBEPositive Net Change
biotechs earnings etfs
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
by Zacks Equity Research
Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
ALNYPositive Net Change CORTPositive Net Change AGIOPositive Net Change RAREPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).
ALKSPositive Net Change VRTXPositive Net Change NTLAPositive Net Change CRSPNegative Net Change
biotechs
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders
by Zacks Equity Research
Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.
VRTXPositive Net Change EDITNegative Net Change CRSPNegative Net Change
biotechs pharmaceuticals
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.
NVSPositive Net Change LLYNegative Net Change INCYPositive Net Change SNDXPositive Net Change
biotechs earnings
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
by Zacks Equity Research
Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.
ZTSPositive Net Change PBYINegative Net Change ADMAPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
by Zacks Equity Research
Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.
BIIBNegative Net Change RHHBYPositive Net Change PBYINegative Net Change
biotechs
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
by Zacks Equity Research
Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
NVSPositive Net Change BMYPositive Net Change GILDNegative Net Change CBAYPositive Net Change
biotechnology biotechs pharmaceuticals
5 Biotech Stocks to Consider for Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.
SRPTNegative Net Change EXELPositive Net Change PBYINegative Net Change EDITNegative Net Change IMCRPositive Net Change
biotechnology biotechs
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
PBYINegative Net Change ADMAPositive Net Change IMVTPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
by Zacks Equity Research
Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.
IMGNPositive Net Change SRPTNegative Net Change PBYINegative Net Change CRVSNegative Net Change
biotechnology biotechs pharmaceuticals
Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY
by Zacks Equity Research
Let's take a look at three biotech/drug companies, BIIB, ZTS, and INCY, slated to release quarterly results on Feb 13.
BIIBNegative Net Change INCYPositive Net Change ZTSPositive Net Change
biotechs medical
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
by Zacks Equity Research
Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.
IMGNPositive Net Change PBYINegative Net Change IMCRPositive Net Change HUMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Incyte's (INCY) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition recently.
NVSPositive Net Change ALKSPositive Net Change INCYPositive Net Change NTLAPositive Net Change
biotechs
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.
ZTSPositive Net Change ADMAPositive Net Change ASNDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
by Zacks Equity Research
Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.
LLYNegative Net Change IMGNPositive Net Change PBYINegative Net Change FHTXNegative Net Change
biotechnology biotechs medical pharmaceuticals